Tyra Biosciences Upsizes ATM to $250M After Exhausting Prior $150M

summarizeSummary

Tyra Biosciences upsized its ATM program from $150 million to $250 million after fully utilizing the prior capacity, adding $100 million in new selling capacity to fund operations.

check_boxKey Events · Financing and Capital Events · TYRA

• ATM Program Upsized to $250M

  The company amended its sales agreement with TD Cowen to increase the maximum aggregate offering price from $150 million to $250 million, adding $100 million in new capacity after fully utilizing the prior limit.

• Prior $150M ATM Fully Exhausted

  As of the date of this prospectus supplement, Tyra had sold all $150 million of shares available under the original ATM program, including $147.9 million in net proceeds raised during Q1 2026.

• Dilution Overhang on Stock

  The new $100 million capacity represents potential dilution of roughly 5% of the current market cap if fully utilized at prevailing prices, adding to the existing overhang from the prior program.

• Strong Cash Position but Ongoing Losses

  Tyra held $353.9 million in cash as of Q2 2026 and reported a $45.6 million net loss, with the ATM proceeds helping extend its cash runway into the second half of 2028.

auto_awesomeAnalysis · TYRA · Life Sciences

Having fully drawn down its existing $150 million at-the-market facility, Tyra Biosciences is reloading with an additional $100 million in capacity, bringing the total program to $250 million. The company raised $147.9 million from the ATM in Q1 alone, extending its cash runway into the second half of 2028, and held $353.9 million in cash as of Q2 2026. While the upsizing provides continued funding flexibility for its clinical pipeline, the steady drip of shares into the market creates an overhang that could pressure the stock, especially with the share price near $31.